Drugs / CD133+ autologous bone marrow stem cell
CD133+ autologous bone marrow stem cell
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00950274 Comparator | Jul 2009 → Mar 2016 | coronary artery disorder, myocardial ischemia | Miltenyi Biotec B.V. & Co. KG | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD133+ autologous bone marrow stem cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00950274 ↗ |
| Modality | Cell therapy | “cell therapy” PMID 32629392 ↗ Jul 2020 |
| Route | Other | “intramyocardially during CABG surgery” NCT00950274 ↗ |